The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture

Journal of the American Geriatrics Society

Volumn 52, Issue 4, 2004, Pages 516-523

  Bach, Mark A ^a   Rockwood, Kenneth ^b,n   Zetterberg, Carl ^c   Thamsborg, Gorm ^d   Hébert, Réjean ^e   Devogelaer, Jean Pierre ^f   Christiansen, Jens Sandahl ^g   Rizzoli, René ^h   Ochsner, J Lockwood ⁱ   Beisaw, Norman ^j   Gluck, Oscar ^k   Yu, Leisure ^l   Schwab, Thomas ^m   Farrington, Jeanne ^a   Taylor, Alice M ^a   Ng, Jennifer ^a   Fuh, Vivian ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Copenhagen Municipal Hospital ^*  (Denmark)

^e UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ OCHSNER CLINIC FOUNDATION   (United States)

^j St Vincent Hospital   (United States)

^k Arizona Rheumatology Center   (United States)

^l LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^m Florida Pharmaceutical Res Group   (United States)

ⁿ Centre for Health Care of the Elderly   (Canada)

more..

Author keywords

Hip fracture; MK 0677; Oral growth hormone secretagogue

Indexed keywords

GROWTH HORMONE SECRETAGOGUE; IBUTAMOREN; PLACEBO; SOMATOMEDIN C;

AGED; ARTICLE; BELGIUM; BLOOD DISEASE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DENMARK; DOUBLE BLIND PROCEDURE; EDEMA; ENDOCRINE DISEASE; FOLLOW UP; GASTROINTESTINAL DISEASE; GERIATRIC CARE; HIP FRACTURE; HUMAN; IMMUNOPATHOLOGY; LYMPHATIC SYSTEM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PAIN; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SWEDEN; SWITZERLAND; THROMBOSIS; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UROGENITAL TRACT DISEASE;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; AGED; DOUBLE-BLIND METHOD; FEMALE; GERIATRIC ASSESSMENT; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HIP FRACTURES; HUMANS; INDOLES; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MENTAL COMPETENCY; QUESTIONNAIRES; RECOVERY OF FUNCTION; SAFETY; SICKNESS IMPACT PROFILE; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 11144357003     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52156.x     Document Type: Article

References (43)

1. Ethans KD, MacKnight C. Hip fracture in the elderly. Postgrad Med 1998;103:157-170.
2. Marottoli R, Berkman L, Cooney L. Decline in physical function following hip fracture. J Am Geriatr Soc 1992;40:861-866.
3. Baudois C, Fardellone P, Bean K et al. Clinical outcomes and mortality after hip fracture: A two-year follow-up study. Bone 1996;18:149S-157S.
4. Magaziner J, Simonsick EM, Hashner TM et al. Predictors of functional recovery 1 year following hospital discharge for hip fracture: A prospective study. J Gerontol 1990;45:M101-M107.
5. Leibson CL, Tosteson ANA, Gabriel SE et al. Mortality, disability and nursing home use for persons with and without hip fracture: A population-based study. J Am Geriatr Soc 2002;50:1644-1650.
6. Kramer AM, Steiner JF, Schlenker RE. Outcomes and costs after hip fracture and stroke: A comparison of rehabilitation settings. JAMA 1997;277:396-404.
7. Langlois JA, Maggi S, Harris T. Self-report of difficulty in performing functional activities identifies a broad range of disability in old age. J Am Geriatr Soc 1996;44:1421-1428.
8. Magaziner J, Hawkes W, Hebel R et al. Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci 2000;55A:M498-M507.
9. Zadik Z, Chalew SA, McCarter RJ Jr et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985;60:513-516.
10. Nonaka I, Miyazawa M, Sukegawa T et al. Muscle fiber atrophy and degeneration induced by experimental immobility and hindlimb suspension. Int J Sports Med 1997;18(Suppl 4):S292-S294.
11. Rudman D, Feller A, Nagraj H et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
12. Hennessey JV, Chromiak JA, Dellaventuras S et al. Growth hormone administration and exercise effects on muscle fibre type and diameter in moderately frail older people. J Am Geriatr Soc 2001;49:852-858.
13. Hubbard R, Pierce A. Anabolic agents in frail elderly patients. Rev Clin Gerontol 2002;12:145-158.
14. Van der Lely AJ, Lanberts SW, Janch KW et al. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000;143:585-592.
15. Patchett AA, Nargund RP, Tata JR et al. Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 1995;92:7001-7005.
16. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Gerety MB, Cornell JE, Mulrow CD et al. The Sickness Impact Profile for Nursing Homes (SIP-NH). J Gerontol 1994;49:M2-M8.
18. Fox KM, Felsenthal G, Hebel JR et al. A portable neuromuscular function assessment for studying recovery from hip fracture. Arch Phys Med Rehab 1998;77:171-176.
19. Guralnik J, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function. Association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85-M94.
20. Jette AM. Functional Status Index. Reliability of a chronic disease evaluation instrument. Arch Phys Med Rehabil 1980;61:395-401.
21. Reuben DB, Siu AL. An objective measure of physical function of elderly outpatients. J Am Geriatr Soc 1990;38:1105-1112.
22. Binder EF, Schechtman KB, Ehsani AA. Effects of exercise training on frailty in community-dwelling older adults: Results of a randomized, controlled trial. J Am Geriatr Soc 2002;50:1921-1928.
23. O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087.
24. Cohen J. Statistical Power Analysis for the Social Sciences, 2nd Ed. Hillsdale, NJ: LEA, 1998.
25. Rockwood K, Stolee P, Fox RA. The use of Goal Attainment Scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 1993;46:1113-1118.
26. Stadnyk K, Calder J, Rockwood K. Testing the measurement properties of the Short Form-36 in a frail elderly population. J Clin Epidemiol 1998;51:827-835.
27. Jaglal S. Lakhaniz, Schatzker J. Reliability, validity and responsiveness of the lower extremity measure for patients with a hip fracture. J Bone Joint Surg 2000;82-A:955-962.
28. Liu PY, Wihsart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-3135.
29. Marcantonio ER, Flacker JM, Michaels M et al. Delirium is independently associated with poor functional recovery after hip fracture. J Am Geriatr Soc 2000;48:618-624.
30. Lindesay J, Rockwood K, Rolfson D. The epidemiology of delirium. In: Lindesay J, Rockwood K, MacDonald A, eds. Delirium in Old Age. Oxford: Oxford University Press, 2002, pp 27-50.
31. Magaziner J, Simonsick EM, Kashner TM et al. Survival experience of aged hip fracture patients. Am J Public Health 1989;79:274-248.
32. Broos PLO, Van Haaften KIK, Stappaerts KH et al. Hip fractures in the elderly. Mortality, functional results and social readaptation. Int Surg 1989;74:191-194.
33. Rasmussen AA, Cullen KJ. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 1998;47:219-233.
34. Yee D. The insulin-like growth factors and breast cancer-revisited. Breast Cancer Res Treat 1998;47:197-199.
35. Surmacz E, Guvakova MA, Nolan MK et al. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998; 47:255-267.
36. Oates AJ, Schumaker LM, Jenkins SB et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998;47:269-281.
37. Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998;58:215-218.
38. Zuckerman JD, Sakales SR, Fahian DR et al. Hip fractures in geriatric patients. Results of an interdisciplinary hospital care program. Clin Orthoped Rel Res 1992;274:213-225.
39. Ogilvie-Harris DJ, Botsford DJ, Hawker RW. Elderly patients with hip fractures. Improved outcome with the use of care maps with high-quality medical and nursing protocols. J Orthop Trauma 1993;7:428-437.
40. Bonjour J-P, Schurch M-A, Rizzoli R. Nutritional aspects of hip fractures. Bone 1996;18:139S-144S.
41. Schurch MA. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. Ann Intern Med 1998;128:801-809.
42. Rockwood K, Hogan HB, MacKnight C. Conceptualization and measurement of frailty in elderly people. Drugs Aging 2000;17:295-302.
43. MacKnight C, Rockwood K. Rasch analysis of the hierarchical assessment of balance and mobility (HABAM). J Clin Epidemiol 2000;53:1242-1247.